Wilfred McKenzie, MD
Internal Medicine · Fort Lauderdale, FLNPI 1245399963
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $615 and has fallen 62.7% since, to $229 in 2025.
Across 143 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$470
- Novo Nordisk$220
- Inari Medical, Inc.$194
- Pfizer$192
- AbbVie$191
- Atricure, Inc.$178
- plus $2K from 31 others
Across 7 payments — averaging $1159.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$8K
- Cipla USA Inc.$98
What the payments were for
- Food & beverage$3,17099%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $470 |
| Novo Nordisk | 15 | $220 |
| Inari Medical, Inc. | 1 | $194 |
| Pfizer | 10 | $192 |
| AbbVie(2 entities) | 11 | $191 |
| Atricure, Inc. | 1 | $178 |
| Merck | 8 | $152 |
| Lilly USA, LLC | 7 | $151 |
| Astellas Pharma US Inc | 6 | $146 |
| Johnson & Johnson | 9 | $125 |
| GSK | 6 | $119 |
| Angiodynamics, Inc. | 1 | $107 |
| Baxter Healthcare | 1 | $83 |
| Amgen | 5 | $76 |
| Therapeuticsmd, Inc. | 4 | $74 |
| Bayer | 4 | $73 |
| Boehringer Ingelheim | 3 | $64 |
| Exact Sciences | 2 | $58 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Hologic Sales And Service, LLC | 2 | $54 |
| Avion Pharmaceuticals | 3 | $43 |
| Abbott | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Novartis | 2 | $31 |
| Vifor Pharma, Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $18 |
| Coopersurgical, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Lupin Inc. | 1 | $16 |
| Millicent US Inc | 1 | $16 |
| Evoke Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,187 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 34 | $39,411 |
| EliquisApixaban | 34 | $34,308 |
| OzempicSemaglutide | 25 | $26,494 |
| TradjentaLinagliptin | 12 | $17,384 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $14,563 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,416 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 13 | $3,740 |
| Omega-3 Acid Ethyl Esters | 11 | $2,405 |
| Nifedipine ErNifedipine | 88 | $1,905 |
| Atorvastatin Calcium | 198 | $1,675 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,454 |
| Ibandronate Sodium | 21 | $1,245 |
| Valsartan | 46 | $1,190 |
| Losartan Potassium | 114 | $1,185 |
| Pantoprazole Sodium | 141 | $1,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $152 | $39,41134 claims |
| PfizerEliquis | $192 | $34,30834 claims |
| Novo NordiskOzempic | $220 | $26,49425 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $119 | $18,97929 claims |
| Boehringer IngelheimTradjenta | $64 | $17,38412 claims |
| AbbVieSynthroid | $191 | $80420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Fort Lauderdale
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Sheetal SharmaFort Lauderdale$184K
- Evan WuFort Lauderdale$114K
- Haytham ElgammalMiami$2.2M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.